BioSpace - BioGeneriX AG News, Search Jobs, Events
9 Nov 2006 ... BioGeneriX AG Janderstasse 3. High-Tech-Park Mannheim Mannheim D-68199 Germany Phone: 49-621-875561-0 Fax: 49-621-87556-33 ...
http://www.biospace.com/company_profile.aspx?CompanyId=70402...
|
XM02 is superior to placebo and equivalent to Neupogen™ in ...
This study was sponsored and funded by BioGeneriX AG. A. del Giglio has a consultancy agreement with BioGeneriX AG. H. Lubenau is an employee of
BioGeneriX ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628928/...
|
BioGeneriX AG and Neose Technologies, Inc. to Host Conference Call ...
1 Nov 2007 ... (BUSINESS WIRE)--BioGeneriX AG, a member of the ratiopharm Group of companies, and Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced ...
http://www.biospace.com/news_story.aspx?NewsEntityId=75876...
|
Neose Technologies, Inc. - Google Finance
The Company has an agreement with BioGeneriX AG to use the GlycoPEGylation technology to develop a long-acting version of G-CSF. Neose Technologies also
has ...
http://www.google.com/finance?q=OTC:NTEC...
|
Neose Technologies, Inc. Announces BioGeneriX AG's Initiation Of ...
(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM: NTEC) today announced that its partner, BioGeneriX AG, a company of the ratiopharm Group, ...
http://www.biospace.com/news_story.aspx?NewsEntityId=36693...
|
1471-2407-8-332 1471-2407 Research article XM02 is superior to ...
Conflicts of interests This study was sponsored and funded by BioGeneriX AG. A. del Giglio has a consultancy agreement with BioGeneriX AG. ...
http://www.biomedcentral.com/content/download/xml/1471-2407-...
|
Evotec Lab Times - Research never stops
Prior to joining Evotec, he served as Chief Financial Officer and Vice President Business Development of BioGeneriX AG, which he co-founded in 2000. ...
http://www.evotec.com/display/archiveDetail/website_part_id/...
|
BMC Cancer
oped by BioGeneriX AG for the treatment of chemother- apy-induced neutropenia. The manufacturing process was developed by Sicor Biotech. ...
http://www.biomedcentral.com/content/pdf/1471-2407-8-332.pdf...
|
Pharmacokinetic and pharmacodynamic profile of new biosimilar ...
BioGeneriX AG, Mannheim, Germany. heinz.lubenau@t-online.de. OBJECTIVE: Filgrastim XM02 is a biosimilar non-glycosylated recombinant methionyl form of
human ...
http://www.ncbi.nlm.nih.gov/pubmed/19344191...
|
The Day In Review: BioSimilar Drug Enters Trial - News, Search ...
March 21, 2007 -- BioGeneriX AG and Neose Technology began the second Phase I trial of a competitor to Amgen's Neulasta, as the war over biosimilar drugs ...
http://www.biospace.com/news_story.aspx?NewsEntityId=49873...
|
